The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of bevacizumab, sorafenib, and low-dose cyclophosphamide (CYC) in children and young adults with refractory solid tumors.
V. M. Santana
No relevant relationships to disclose
S. D. Baker
No relevant relationships to disclose
B. McCarville
Research Funding - GE Healthcare
C. F. Stewart
No relevant relationships to disclose
J. Wu
No relevant relationships to disclose
C. Billups
No relevant relationships to disclose
S. L. Spunt
No relevant relationships to disclose
W. L. Furman
No relevant relationships to disclose
L. M. McGregor
No relevant relationships to disclose
S. Hu
No relevant relationships to disclose
J. C. Panetta
No relevant relationships to disclose
W. E. Reddick
No relevant relationships to disclose
A. Davidoff
No relevant relationships to disclose
W. H. Leung
No relevant relationships to disclose
F. Navid
No relevant relationships to disclose